Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 62

1.

Specimen quality evaluation in Canadian biobanks participating in the COEUR repository.

Le Page C, Köbel M, de Ladurantaye M, Rahimi K, Madore J, Babinszky S, Bachvarov DR, Bachvarova M, Beauchamp MC, Cass CE, Chadwick D, Colleen C, Damaraju S, Dufour J, Gotlieb WH, Kalloger SE, Portelance L, McAlpine JN, Matte I, Piché A, Shaw P, Roehrl MH, Vanderhyden BC, Watson PH, Huntsman DG, Provencher DM, Mes-Masson AM.

Biopreserv Biobank. 2013 Apr;11(2):83-93. doi: 10.1089/bio.2012.0044. Erratum in: Biopreserv Biobank. 2013 Aug;11(4):257. Roehrl, Michael H A [added].

PMID:
24845429
[PubMed - in process]
2.

ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts.

Wiegand KC, Sy K, Kalloger SE, Li-Chang H, Woods R, Kumar A, Streutker CJ, Hafezi-Bakhtiari S, Zhou C, Lim HJ, Huntsman DG, Clarke B, Schaeffer DF.

Hum Pathol. 2014 Jun;45(6):1258-68. doi: 10.1016/j.humpath.2014.02.006. Epub 2014 Feb 20.

PMID:
24767857
[PubMed - indexed for MEDLINE]
3.

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.

Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.

BMC Cancer. 2014 Feb 22;14:120. doi: 10.1186/1471-2407-14-120.

PMID:
24559118
[PubMed - in process]
Free PMC Article
4.

Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma.

Townsend KN, Spowart JE, Huwait H, Eshragh S, West NR, Elrick MA, Kalloger SE, Anglesio M, Watson PH, Huntsman DG, Lum JJ.

PLoS One. 2013 Dec 23;8(12):e82406. doi: 10.1371/journal.pone.0082406. eCollection 2013.

PMID:
24376535
[PubMed - in process]
Free PMC Article
5.

Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research.

Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG.

PLoS One. 2013 Sep 27;8(9). doi: 10.1371/annotation/ffcaf179-872f-470b-8bb6-f06d8ba6d03a. eCollection 2013.

PMID:
24116245
[PubMed - as supplied by publisher]
Free PMC Article
6.

Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry.

Ali RH, Kalloger SE, Santos JL, Swenerton KD, Gilks CB.

Int J Gynecol Pathol. 2013 Nov;32(6):529-35. doi: 10.1097/PGP.0b013e31827630eb.

PMID:
24071867
[PubMed - indexed for MEDLINE]
7.

Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review.

Kommoss S, Gilks CB, Kommoss F, Chow C, Hilpert F, du Bois A, Köbel M, Huntsman DG, Anglesio M, Kalloger SE, Pfisterer J.

Histopathology. 2013 Nov;63(5):704-12. doi: 10.1111/his.12219. Epub 2013 Sep 2.

PMID:
24033430
[PubMed - indexed for MEDLINE]
8.

Type-specific cell line models for type-specific ovarian cancer research.

Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG.

PLoS One. 2013 Sep 4;8(9):e72162. doi: 10.1371/journal.pone.0072162. eCollection 2013.

PMID:
24023729
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.

Köbel M, Kalloger SE, Lee S, Duggan MA, Kelemen LE, Prentice L, Kalli KR, Fridley BL, Visscher DW, Keeney GL, Vierkant RA, Cunningham JM, Chow C, Ness RB, Moysich K, Edwards R, Modugno F, Bunker C, Wozniak EL, Benjamin E, Gayther SA, Gentry-Maharaj A, Menon U, Gilks CB, Huntsman DG, Ramus SJ, Goode EL; Ovarian Tumor Tissue Analysis consortium.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1677-86. doi: 10.1158/1055-9965.EPI-13-0391. Epub 2013 Jul 23.

PMID:
23880734
[PubMed - indexed for MEDLINE]
10.

Reproducibility of histological cell type in high-grade endometrial carcinoma.

Han G, Sidhu D, Duggan MA, Arseneau J, Cesari M, Clement PB, Ewanowich CA, Kalloger SE, Köbel M.

Mod Pathol. 2013 Dec;26(12):1594-604. doi: 10.1038/modpathol.2013.102. Epub 2013 Jun 28.

PMID:
23807777
[PubMed - in process]
11.

Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells.

Diep CH, Charles NJ, Gilks CB, Kalloger SE, Argenta PA, Lange CA.

Cell Cycle. 2013 May 1;12(9):1433-49. doi: 10.4161/cc.24550. Epub 2013 Apr 10.

PMID:
23574718
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.

Altman AD, Nelson GS, Ghatage P, McIntyre JB, Capper D, Chu P, Nation JG, Karnezis AN, Han G, Kalloger SE, Köbel M.

Mod Pathol. 2013 Sep;26(9):1255-63. doi: 10.1038/modpathol.2013.55. Epub 2013 Apr 5.

PMID:
23558569
[PubMed - indexed for MEDLINE]
13.

BRCA1 immunohistochemical staining as a prognostic indicator in uterine serous carcinoma.

Beirne JP, Quinn JE, Maxwell P, Kalloger SE, McAlpine J, Gilks CB, Harley IJ, McCluggage WG.

Int J Gynecol Cancer. 2013 Jan;23(1):113-8. doi: 10.1097/IGC.0b013e3182798188.

PMID:
23221734
[PubMed - indexed for MEDLINE]
14.

Quantification of ER/PR expression in ovarian low-grade serous carcinoma.

Escobar J, Klimowicz AC, Dean M, Chu P, Nation JG, Nelson GS, Ghatage P, Kalloger SE, Köbel M.

Gynecol Oncol. 2013 Feb;128(2):371-6. doi: 10.1016/j.ygyno.2012.10.013. Epub 2012 Oct 24.

PMID:
23103384
[PubMed - indexed for MEDLINE]
15.

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.

Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, Damaraju S, Fereday S, Winterhoff BJ, Kalloger SE, Senz J, Yang W, Steed H, Allo G, Ferguson S, Shaw P, Teoman A, Garcia JJ, Schoolmeester JK, Bakkum-Gamez J, Tinker AV, Bowtell DD, Huntsman DG, Gilks CB, McAlpine JN.

J Pathol. 2013 Jan;229(1):111-20. doi: 10.1002/path.4088.

PMID:
22899400
[PubMed - indexed for MEDLINE]
16.

Architectural patterns of ovarian/pelvic high-grade serous carcinoma.

Bromley AB, Altman AD, Chu P, Nation JG, Nelson GS, Ghatage P, Kalloger SE, Han G, Köbel M.

Int J Gynecol Pathol. 2012 Sep;31(5):397-404. doi: 10.1097/PGP.0b013e31824c2372.

PMID:
22833078
[PubMed - indexed for MEDLINE]
17.

Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.

Schrader KA, Hurlburt J, Kalloger SE, Hansford S, Young S, Huntsman DG, Gilks CB, McAlpine JN.

Obstet Gynecol. 2012 Aug;120(2 Pt 1):235-40. doi: 10.1097/AOG.0b013e31825f3576.

PMID:
22776961
[PubMed - indexed for MEDLINE]
18.

Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes.

Milne K, Alexander C, Webb JR, Sun W, Dillon K, Kalloger SE, Gilks CB, Clarke B, Köbel M, Nelson BH.

J Transl Med. 2012 Feb 27;10:33. doi: 10.1186/1479-5876-10-33.

PMID:
22369276
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Use of mismatch repair immunohistochemistry and microsatellite instability testing: exploring Canadian practices.

Kalloger SE, Allo G, Mulligan AM, Pollett A, Aronson M, Gallinger S, Torlakovic EE, Clarke BA.

Am J Surg Pathol. 2012 Apr;36(4):560-9. doi: 10.1097/PAS.0b013e31823f3b28.

PMID:
22301492
[PubMed - indexed for MEDLINE]
20.

BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.

McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB.

Mod Pathol. 2012 May;25(5):740-50. doi: 10.1038/modpathol.2011.211. Epub 2012 Jan 27.

PMID:
22282309
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk